{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:02:48Z","timestamp":1776772968732,"version":"3.51.2"},"reference-count":66,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The National Health and Medical Research Council","award":["APP2014896"],"award-info":[{"award-number":["APP2014896"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,2,18]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Calcium channel blockers (CCB), a commonly prescribed antihypertensive (AHT) medicine, may be associated with increased risk of breast cancer. The proposed study aims to examine whether long-term CCB use is associated with the development of breast cancer and to characterise the dose\u2013response nature of any identified association, to inform future hypertension management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The study will use data from 2 of Australia\u2019s largest cohort studies; the Australian Longitudinal Study on Women\u2019s Health, and the 45 and Up Study, combined with the Rotterdam Study. Eligible women will be those with diagnosed hypertension, no history of breast cancer and no prior CCB use at start of follow-up (2004\u20132009). Cumulative dose-duration exposure to CCB and other AHT medicines will be captured at the earliest date of: the outcome (a diagnosis of invasive breast cancer); a competing risk event (eg, bilateral mastectomy without a diagnosis of breast cancer, death prior to any diagnosis of breast cancer) or end of follow-up (censoring event). Fine and Gray competing risks regression will be used to assess the association between CCB use and development of breast cancer using a generalised propensity score to adjust for baseline covariates. Time-varying covariates related to interaction with health services will also be included in the model. Data will be harmonised across cohorts to achieve identical protocols and a two-step random effects individual patient-level meta-analysis will be used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was obtained from the following Human research Ethics Committees: Curtin University (ref No. HRE2022-0335), NSW Population and Health Services Research Ethics Committee (2022\/ETH01392\/2022.31), ACT Research Ethics and Governance Office approval under National Mutual Acceptance for multijurisdictional data linkage research (2022.STE.00208). Results of the proposed study will be published in high-impact journals and presented at key scientific meetings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\" xlink:href=\"NCT05972785\">NCT05972785<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-080982","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T21:57:50Z","timestamp":1709935070000},"page":"e080982","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Association between long-term use of calcium channel blockers (CCB) and the risk of breast cancer: a retrospective longitudinal observational study protocol"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05972785","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4285-9409","authenticated-orcid":false,"given":"Chau","family":"Ho","sequence":"first","affiliation":[{"name":"School of Population Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ninh Thi","family":"Ha","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4296-4161","authenticated-orcid":false,"given":"David","family":"Youens","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia"},{"name":"Cardiovascular Epidemiology Research Centre, School of Population and Global Health, The University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter P","family":"Abhayaratna","sequence":"additional","affiliation":[{"name":"Canberra Health Services, Canberra, Australian Capital Territory, Australia"},{"name":"School of Medicine and Psychology, Australian National University, Canberra, Australian Capital Territory, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8033-6123","authenticated-orcid":false,"given":"Max K","family":"Bulsara","sequence":"additional","affiliation":[{"name":"Institute for Health Research, The University of Notre Dame Australia, Fremantle, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0040-4753","authenticated-orcid":false,"given":"Jeffery David","family":"Hughes","sequence":"additional","affiliation":[{"name":"Curtin Medical School, Curtin University, Perth, Western Australia, Australia"},{"name":"PainChek, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gita","family":"Mishra","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Queensland, Saint Lucia, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"School of Population Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"The NHMRC Medicines Intelligence Centre of Research Excellence, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B","family":"Preen","sequence":"additional","affiliation":[{"name":"The NHMRC Medicines Intelligence Centre of Research Excellence, Sydney, New South Wales, Australia"},{"name":"School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M","family":"Reid","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikje","family":"Ruiter","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus MC\u2014University Medical Center, Rotterdam, Zuid-Holland, Netherlands"},{"name":"Department of Internal Medicine, Maasstad Hospital, Rotterdam, Zuid-Holland, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christobel M","family":"Saunders","sequence":"additional","affiliation":[{"name":"Medical School, The University of Western Australia, Perth, Western Australia, Australia"},{"name":"Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"The Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-9762","authenticated-orcid":false,"given":"Bruno H","family":"Stricker","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus MC\u2014University Medical Center, Rotterdam, Zuid-Holland, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank J A","family":"van Rooij","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus MC\u2014University Medical Center, Rotterdam, Zuid-Holland, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Wright","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia"},{"name":"Medical School, The University of Western Australia, Perth, Western Australia, Australia"},{"name":"Fiona Stanley Hospital, Perth, Western Australia, Australia"},{"name":"School of Medicine, University of Tasmania, Hobart, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8742-7151","authenticated-orcid":false,"given":"Rachael","family":"Moorin","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia"},{"name":"School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"2025120618534477000_14.3.e080982.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025120618534477000_14.3.e080982.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.08.010"},{"key":"2025120618534477000_14.3.e080982.3","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.119.14240"},{"key":"2025120618534477000_14.3.e080982.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68770-9"},{"key":"2025120618534477000_14.3.e080982.5","doi-asserted-by":"crossref","unstructured":"World Health Organisation . A global brief on hypertension: silent killer, global public health crisis. document number: WHO\/DCO\/WHD\/2013.2 Geneva; 2013. WHO doi:10.5005\/ijopmr-24-1-2","DOI":"10.5005\/ijopmr-24-1-2"},{"key":"2025120618534477000_14.3.e080982.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"2025120618534477000_14.3.e080982.7","unstructured":"National Vascular Disease Prevention Alliance . Guidelines for the management of absolute cardiovascular disease risk; 2012."},{"key":"2025120618534477000_14.3.e080982.8","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(96)00219-1"},{"key":"2025120618534477000_14.3.e080982.9","doi-asserted-by":"publisher","DOI":"10.1038\/284555a0"},{"key":"2025120618534477000_14.3.e080982.10","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.22.6349"},{"key":"2025120618534477000_14.3.e080982.11","doi-asserted-by":"publisher","DOI":"10.1038\/nature09583"},{"key":"2025120618534477000_14.3.e080982.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7301.1528"},{"key":"2025120618534477000_14.3.e080982.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113649","article-title":"Nifedipine promotes the proliferation and migration of breast cancer cells","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"},{"key":"2025120618534477000_14.3.e080982.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081222","article-title":"Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in Dystrophic Mdx mice","volume":"8","author":"Altamirano","year":"2013","journal-title":"PLoS ONE"},{"key":"2025120618534477000_14.3.e080982.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2017.08.012"},{"key":"2025120618534477000_14.3.e080982.16","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","article-title":"Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years","volume":"173","author":"Li","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2025120618534477000_14.3.e080982.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009147","article-title":"Calcium channel blockers and cancer: a risk analysis using the UK clinical practice research Datalink (CPRD)","volume":"6","author":"Grimaldi-Bensouda","year":"2016","journal-title":"BMJ Open"},{"key":"2025120618534477000_14.3.e080982.18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-016-0720-6","article-title":"Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women","volume":"18","author":"Wilson","year":"2016","journal-title":"Breast Cancer Res"},{"key":"2025120618534477000_14.3.e080982.19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092344","article-title":"Calcium channel blocker use and the risk for breast cancer: a population-based nested case-control study","volume":"14","author":"Rotshild","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025120618534477000_14.3.e080982.20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/aje\/kww217","article-title":"Risk of breast cancer with long-term use of calcium channel blockers or angiotensin-converting enzyme inhibitors among older women","volume":"185","author":"Raebel","year":"2017","journal-title":"Am J Epidemiol"},{"key":"2025120618534477000_14.3.e080982.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159672","article-title":"The use of antihypertensive medication and the risk of breast cancer in a case-control study in a Spanish population: the MCC-Spain study","volume":"11","author":"G\u00f3mez-Acebo","year":"2016","journal-title":"PLoS One"},{"key":"2025120618534477000_14.3.e080982.22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.609901","article-title":"Association between antihypertensive medication use and breast cancer: a systematic review and meta-analysis","volume":"12","author":"Xie","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025120618534477000_14.3.e080982.23","unstructured":"National Heart Foundation of Australia . Guideline for the diagnosis and management of hypertension in adults \u2013 2016. Melbourne. National Heart Foundation of Australia; 2016."},{"key":"2025120618534477000_14.3.e080982.24","first-page":"169","article-title":"Clinical practice guideline for cardiovascular risk management in the Netherlands","volume":"66","author":"Smulders","year":"2008","journal-title":"Neth J Med"},{"key":"2025120618534477000_14.3.e080982.25","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0492-9"},{"key":"2025120618534477000_14.3.e080982.26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.4722","article-title":"How Pharmacoepidemiology networks can manage distributed analyses to improve Replicability and transparency and minimize bias","volume":"29","author":"Platt","year":"2020","journal-title":"Pharmacoepidemiology and Drug"},{"key":"2025120618534477000_14.3.e080982.27","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv110"},{"key":"2025120618534477000_14.3.e080982.28","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1093\/ije\/dyac104","article-title":"Cohort profile update: the 45 and up study","volume":"52","author":"Bleicher","year":"2023","journal-title":"Int J Epidemiol"},{"key":"2025120618534477000_14.3.e080982.29","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-020-00640-5"},{"key":"2025120618534477000_14.3.e080982.30","doi-asserted-by":"crossref","DOI":"10.17061\/phrp2541546","article-title":"Using Australian pharmaceutical benefits scheme data for pharmacoepidemiological research: challenges and approaches","volume":"25","author":"Page","year":"2015","journal-title":"Public Health Res Pract"},{"key":"2025120618534477000_14.3.e080982.31","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv133"},{"key":"2025120618534477000_14.3.e080982.32","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw075"},{"key":"2025120618534477000_14.3.e080982.33","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1656"},{"key":"2025120618534477000_14.3.e080982.34","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5407"},{"key":"2025120618534477000_14.3.e080982.35","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi307"},{"key":"2025120618534477000_14.3.e080982.36","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology . ATC classification index with Ddds Oslo, Norway. 2023. Available: https:\/\/www.whocc.no\/atc_ddd_index_and_guidelines\/atc_ddd_index"},{"key":"2025120618534477000_14.3.e080982.37","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3459"},{"key":"2025120618534477000_14.3.e080982.38","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/pds.5340","article-title":"Using multiple random index dates with the reverse waiting time distribution improves precision of estimated prescription durations","volume":"30","author":"B\u00f8dkergaard","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120618534477000_14.3.e080982.39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2147\/CLEP.S153496","article-title":"Operationalization and validation of a novel method to calculate adherence to Polypharmacy with refill data from the Australian pharmaceutical benefits scheme (PBS) database","volume":"10","author":"Arnet","year":"2018","journal-title":"Clin Epidemiol"},{"key":"2025120618534477000_14.3.e080982.40","unstructured":"Chronicle of the International statistical classification of diseases and related health problems, tenth revision, Australian modification (ICD-10-AM) first edition to eleventh edition; 2019. Available: https:\/\/www.ihacpa.gov.au\/sites\/default\/files\/2022-08\/icd-10-am_chronicle_-_eleventh_edition.pdf"},{"key":"2025120618534477000_14.3.e080982.41","unstructured":"Organization WH . International statistical classification of diseases and related health problems: alphabetical index. World Health Organization; 2004."},{"key":"2025120618534477000_14.3.e080982.42","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/ijc.28803","article-title":"Is carcinoma in situ a precursor lesion of invasive breast cancer","volume":"135","author":"To","year":"2014","journal-title":"Int J Cancer"},{"key":"2025120618534477000_14.3.e080982.43","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-6608-y","article-title":"Potential biomarkers of ductal carcinoma in situ progression","volume":"20","author":"Dettogni","year":"2020","journal-title":"BMC Cancer"},{"key":"2025120618534477000_14.3.e080982.44","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-1"},{"key":"2025120618534477000_14.3.e080982.45","unstructured":"Cancer Australia. . Risk factors for breast cancer: A review of the evidence, cancer Australia, Surry hills, NSW; 2018."},{"key":"2025120618534477000_14.3.e080982.46","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The validity of the Rx-risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (ATC) classification system","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ Open"},{"key":"2025120618534477000_14.3.e080982.47","doi-asserted-by":"publisher","DOI":"10.2307\/2670170"},{"key":"2025120618534477000_14.3.e080982.48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/0470090456.ch7","volume-title":"Applied Bayesian modeling and causal inference from incomplete-data perspectives","volume":"226164","author":"Hirano","year":"2004"},{"key":"2025120618534477000_14.3.e080982.49","doi-asserted-by":"crossref","unstructured":"Hirano K , Imbens G . The propensity score with continuous treatments. In: Gelman A , Meng X , eds. Applied Bayesian Modeling and Causal Inference from Incomplete-Data Perspectives. Sussex: Wiley Interscience, 2004: 73\u201384. doi:10.1002\/0470090456","DOI":"10.1002\/0470090456.ch7"},{"key":"2025120618534477000_14.3.e080982.50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1536867X1401400110","article-title":"Estimating the dose-response function through a generalized linear model approach","volume":"14","author":"Guardabascio","year":"2014","journal-title":"STATA J"},{"key":"2025120618534477000_14.3.e080982.51","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1467-985X.2011.01000.x","article-title":"Evaluating continuous training programmes by using the generalized propensity score","volume":"175","author":"Kluve","year":"2012","journal-title":"J Royal Statis Soc Series A"},{"key":"2025120618534477000_14.3.e080982.52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1162\/REST_a_00177","article-title":"Estimating the effects of length of exposure to instruction in a training program: the case of job Corps","volume":"94","author":"Flores","year":"2012","journal-title":"Rev Econom Statis"},{"key":"2025120618534477000_14.3.e080982.53","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hec.3088","article-title":"Threshold effects in nonlinear models with an application to the social capital-retirement-health relationship","volume":"23","author":"Gannon","year":"2014","journal-title":"Health Econ"},{"key":"2025120618534477000_14.3.e080982.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2004.05.009"},{"key":"2025120618534477000_14.3.e080982.55","unstructured":"StataCorp . Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC, 2017."},{"key":"2025120618534477000_14.3.e080982.56","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1186\/1471-2288-14-79","article-title":"Systematic review of methods for individual patient data meta- analysis with binary outcomes","volume":"14","author":"Thomas","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025120618534477000_14.3.e080982.57","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/jrsm.1297","article-title":"Methods for evidence synthesis in the case of very few studies","volume":"9","author":"Bender","year":"2018","journal-title":"Res Synth Methods"},{"key":"2025120618534477000_14.3.e080982.58","unstructured":"Australian Longitudinal Study on Women\u2019s Health . Current HREC approvals for ALSWH data linkage [4\/07\/2023]. n.d. Available: https:\/\/alswh.org.au\/alswh-hrec-approvals\/"},{"key":"2025120618534477000_14.3.e080982.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0706892"},{"key":"2025120618534477000_14.3.e080982.60","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059669","article-title":"Diagnostic pathways for breast cancer in 10 International cancer Benchmarking partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and Registry data","volume":"12","author":"Vedsted","year":"2022","journal-title":"BMJ Open"},{"key":"2025120618534477000_14.3.e080982.61","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41371-023-00835-9","article-title":"Genetic proxies for calcium channel blockers and cancer: a mendelian randomization study","volume":"37","author":"Fan","year":"2023","journal-title":"J Hum Hypertens"},{"key":"2025120618534477000_14.3.e080982.62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003897","article-title":"Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: a mendelian randomization analysis","volume":"19","author":"Yarmolinsky","year":"2022","journal-title":"PLOS Med"},{"key":"2025120618534477000_14.3.e080982.63","doi-asserted-by":"publisher","DOI":"10.1177\/003591576505800503"},{"key":"2025120618534477000_14.3.e080982.64","unstructured":"Rothman KJ , Greenland S , Lash TL . Modern epidemiology. Wolters Kluwer Health\/Lippincott Williams & Wilkins Philadelphia, 2008."},{"key":"2025120618534477000_14.3.e080982.65","doi-asserted-by":"publisher","DOI":"10.1038\/445257a"},{"key":"2025120618534477000_14.3.e080982.66","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-1"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-080982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T02:53:59Z","timestamp":1765076039000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-080982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":66,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,8]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/bmjopen-2023-080982"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-080982","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}